Aktienrückkauf: Bekanntmachung nach Artikel 5 Abs. 1 b) und Abs. 3 der Verordnung (EU) Nr. 596/2014
Einladung zur ordentlichen Hauptversammlung
Konzernergebnis Geschäftsjahr 2017/18
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
KFM-Mittelstandsanleihen-Barometer - Die "5,25%-Capital Stage-Hybrid-Wandelanleihe"
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
MELDUNG VOM 07.07.2017 15:28
Meldung drucken Artikel weiterleiten
Business news for the stock market
Pressefach Pressefach

MPH Mittelständische Pharma Holding AG: Change in Management Board

Berlin (pta021/07.07.2017/15:28) - In today's meeting, the Supervisory Board of MPH Mittelständische Pharma Holding AG ("MPH" or the "Company") accepted the wish of Dr. Christian Pahl to not extend his contract as Management Board Member beyond the current term ending 31 July 2017. The Supervisory Board regrets this decision. Dr. Pahl has been a member of the Management Board of MPH since May 2010.

Upon leaving the Company at the end of his term on his own request, Dr. Pahl wishes to devote himself to new tasks.

The Supervisory Board would like to thank Dr. Pahl for his productive cooperation over the past years as well as his dedication to the success of the Company. During his tenure at MPH, the Company's market valuation increased notably and important milestones in the growth of the Company have been achieved.

Mr. Patrick Brenske will lead the Company as sole Chief Executive Officer going forward.

About MPH Mittelständische Pharma Holding AG:

MPH Mittelständische Pharma Holding AG was founded in November 2008. Since September 2009, the company is listed on the Frankfurt Stock Exchange. MPH AG is an investment company with the strategic focus on the acquisition, construction and sale of companies. Our investment focus is on fast-growing insurance and private financed segments of the healthcare market. This includes both, the market for special medicaments for chronic diseases and medical treatments with a high proportion of self-pay, such as, for example, in the field of beauty medicine. For all investments, the requirement of a low-cost supply - usually price leadership - is at the highest quality.


Aussender: MPH Mittelständische Pharma Holding AG
Grünauer Straße 5
12557 Berlin
Ansprechpartner: MPH AG - Investor Relations
Tel.: +49 30 8973086-60
ISIN(s): DE000A0L1H32 (share)
Börsen: free market in Dusseldorf, basic board in Frankfurt, free market in Stuttgart; open market in Berlin, Tradegate
MPH Mittelständische Pharma Holding AG
25.06.2018 13:30
Preise für Camping: Deutschland nur im Mittelfeld
25.06.2018 11:30
TPA erweitert und verjüngt die Eigentümerbasis deutlich
TPA Steuerberatung GmbH
25.06.2018 10:00
Arrow und next layer kooperieren in Österreich
Arrow ECS Internet Security AG
25.06.2018 06:15
Share-Economy-Angebote auf absteigendem Ast
23.06.2018 16:10
Online-Marketing-Ausbildung im Sommer
22.06.2018 12:30
Peer-to-Peer-Bezahlsysteme immer beliebter
Weitere News anzeigen